Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile.

Abstract

Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis. Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa. Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series. The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.

• Authors: Giulia Ganzetti, Anna Campanati, E Molinelli, A Offidani
• Journal: Current drug safety (Curr Drug Saf) Vol. 11 Issue 1 Pg. 12-21 ( 2016) ISSN: 2212-3911 [Electronic] United Arab Emirates
• PMID: 26463243 (Publication Type: Journal Article, Review)

Chemical References

• Inflammation Mediators
• Adalimumab

Topics

• Adalimumab (therapeutic use)
• Animals
• Biological Therapy (adverse effects, methods)
• Drug-Related Side Effects and Adverse Reactions (diagnosis, etiology, immunology)
• Hidradenitis Suppurativa (diagnosis, drug therapy, immunology)
• Humans
• Inflammation Mediators (antagonists & inhibitors, immunology)
• Off-Label Use
• Psoriasis (diagnosis, drug therapy, immunology)
• Skin Diseases (diagnosis, drug therapy, immunology)